A double blind, randomised, placebo controlled, parallel group study of Sativex [dronabinol/cannabidiol] when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis

Trial Profile

A double blind, randomised, placebo controlled, parallel group study of Sativex [dronabinol/cannabidiol] when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2013

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2012 Planned number of patients changed from 218 to 312 as reported by European Clinical Trials Database.
    • 08 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2008 Interim results have been reported in a media release from GW Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top